Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product

Core Insights - Philip Morris International Inc. presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC) regarding its IQOS heated tobacco products [1] - The TPSAC is composed of independent scientific researchers and provides nonbinding recommendations to the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) [1] - The meeting held on October 7 was part of the FDA's customary review process for PMI's request to continue marketing its IQOS products [1]